This article analyzes the studies concerning the CBT treatment effectiveness in major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder (PD), and social anxiety disorder (SAD).

Main part

During foreign and domestic studies analysis (randomized studies, behavioral therapy, individual and group therapy, only control groups studies in order to maintain low level of heterogeneity) reliable data were obtained proving high efficiency of CBT treatment effectiveness in MDD, GAD, PD, SAD. CBT is a cost-effective treatment. The high efficacy, confirmed by numerous empirical studies and the economic benefits of CBT, contribute to the high prevalence of this treatment type for several mental disorders throughout the world. In addition, CBT has a significant positive impact on secondary symptoms associated with anxiety disorders, namely sleep disturbances and anxiety sensitivity formation (Ghahramanlou, 2003).

Cognitive-behavioral therapy is the first line of treatment in helping people with anxiety-depressive and other types of mental disorders in many developed countries, such as the United States and the United Kingdom.
In addition, it was important to establish whether the quality of research has improved in recent years. In a fact, 29.5% of studies conducted in 2010 and later were rated as highly effective, while only 12% of studies conducted earlier met this assessment. 52% of all high-effective studies were conducted after 2010.

Conclusion

The research results analysis suggests that the use of CBT in the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder (PD), and social anxiety disorder (SAD) is highly effective.

CBT is a cost-effective treatment. Confirmed by numerous empirical studies, high efficacy and the economic benefits of CBT contribute to the high prevalence of this treatment type for several mental disorders around the world.

Literature

Whiteford HA, Degenhardt L, Rehm J et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575-86. Steel Z, Marnane C, Iranpour C et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. Int J Epidemiol 2014;43:476-93.

Gustavsson A, Svensson M, Jacobi F et al. Cost of disorders of the brain in Europe 2010. EurNeuropsychopharmacol 2011;21:71879.
Hu T-W. Perspectives: an international review of the national cost estimates of mental illness, 1990-2003. J Mental Health Policy Econ 2006;9:3-13.
Chisholm D, Sweeny K, Sheehan P et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry 2016;3:415-24.
Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848-56
Cuijpers P, Sijbrandij M, Koole SL et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a metaanalysis of direct comparisons. World Psychiatry 2013;12:137-48.
Acarturk C, Cuijpers P, van StratenA et al. Psychological treatment of social anxiety disorder: a meta-analysis. Psychol Med 2009;39:241-54.
Cuijpers P, Sijbrandij M, Koole S et al. Psychological treatment of generalized anxiety disorder: a meta-analysis. World Journal of Biological Psychiatry 2014;34:130-40.
Sanchez-Meca J, Rosa-Alcazar AI, Marхn-Martхnez F et al. Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. ClinPsychol Rev 2010;30:37-50.